The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

被引：1
|
作者：
Ashcroft, John
de Tute, Ruth M.
Cairns, David A.
Fletcher, Marie
Owen, Roger G.
Rawstron, Andy
O'Connor, Sheila J. M.
Williams, Cathy D.
Snowden, John A.
Cavenagh, J. D.
Parrish, Christopher
Morris, Treen
Brown, Julia M. B.
Cook, Gordon
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3378.3378
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3378
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Minimal residual disease is highly predictive of outcome in myeloma: results from MRC Myeloma IX
    Owen, R. G.
    de Tute, R. M.
    Child, J. A.
    Davies, F. E.
    Gregory, W.
    Bell, S.
    Szubert, A.
    Navarro-Coy, N.
    Drayson, M. T.
    Feyler, S.
    Ross, F.
    Cook, G.
    Jackson, G. H.
    Morgan, G. J.
    Rawstron, A. C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 12 - 13
  • [22] Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance
    Sweiss, Karen
    Hofmeister, Craig C.
    Zappia, Maria
    Frolov, Maxim
    Benevolenskaya, Elizaveta
    Quigley, John G.
    Kadkol, Shrihari
    Sborov, Douglas W.
    Rondelli, Damiano
    Patel, Pritesh
    BLOOD, 2022, 140 : 7304 - 7305
  • [23] Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
    Schmitz, Alexander
    Brondum, Rasmus Froberg
    Johnsen, Hans Erik
    Mellqvist, Ulf-Henrik
    Waage, Anders
    Gimsing, Peter
    Bruinink, Davine Hofste Op
    van der Velden, Vincent
    van der Holt, Bronno
    Hansson, Markus
    Andersen, Niels Frost
    Frolund, Ulf Christian
    Helleberg, Carsten
    Schjesvold, Fredrik H.
    Ahlberg, Lucia
    Gulbrandsen, Nina
    Andreasson, Bjorn
    Lauri, Birgitta
    Haukas, Einar
    Bodker, Julie Stove
    Roug, Anne Stidsholt
    Bogsted, Martin
    Severinsen, Marianne T.
    Gregersen, Henrik
    Abildgaard, Niels
    Sonneveld, Pieter
    Dybkaer, Karen
    BMC CANCER, 2022, 22 (01)
  • [24] Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
    Alexander Schmitz
    Rasmus Froberg Brøndum
    Hans Erik Johnsen
    Ulf-Henrik Mellqvist
    Anders Waage
    Peter Gimsing
    Davine Hofste op Bruinink
    Vincent van der Velden
    Bronno van der Holt
    Markus Hansson
    Niels Frost Andersen
    Ulf Christian Frølund
    Carsten Helleberg
    Fredrik H. Schjesvold
    Lucia Ahlberg
    Nina Gulbrandsen
    Bjorn Andreasson
    Birgitta Lauri
    Einar Haukas
    Julie Støve Bødker
    Anne Stidsholt Roug
    Martin Bøgsted
    Marianne T. Severinsen
    Henrik Gregersen
    Niels Abildgaard
    Pieter Sonneveld
    Karen Dybkær
    BMC Cancer, 22
  • [25] Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study
    Hahn, Theresa E.
    Wallace, Paul K.
    Fraser, Raphael
    Fei, Mingwei
    Tario, Joseph D.
    Howard, Alan
    Zhang, Yali
    Blackwell, Beth
    Brunstein, Claudio G.
    Efebera, Yvonne A.
    Geller, Nancy
    Giralt, Sergio A.
    Hari, Parameswaran
    Knust, Kristin
    Koreth, John
    Krishnan, Amrita
    Landau, Heather
    Shah, Nina
    Somlo, George
    Stadtmauer, Edward A.
    Vogl, Dan T.
    Vesole, David H.
    McCarthy, Philip L.
    Pasquini, Marcelo C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [26] Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM).
    Oliva, Stefania
    Genuardi, Elisa
    Belotti, Angelo
    Frascione, Pio Manlio Mirko
    Galli, Monica
    Capra, Andrea
    Offidani, Massimo
    Vozella, Federico
    Zambello, Renato
    Auclair, Daniel
    Kirsch, Ilan
    Ruggeri, Marina
    Jacob, Allison
    Ledda, Antonio
    Corradini, Paolo
    Gilestro, Milena
    Zamagni, Elena
    Musto, Pellegrino
    Boccadoro, Mario
    Gay, Francesca
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] A systematic review of measurable residual disease (MRD) assessment characteristics in myeloma trials from 2015-2020
    Van Oekelen, Oliver
    Birrer, Nicole
    Wesson, William
    Galate, Vince
    Goodman, Aaron
    Abdallah, Al-Ola
    Chakraborty, Rajshekhar
    Prasad, Vinay
    Mohyuddin, Ghulam Rehman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S64 - S65
  • [28] Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)
    Lane, Andrew A.
    Sweet, Kendra L.
    Wang, Eunice S.
    Donnellan, William B.
    Walter, Roland B.
    Stein, Anthony S.
    Rizzieri, David A.
    Carraway, Hetty E.
    Mantzaris, Ioannis
    Prebet, Thomas
    Maris, Michael B.
    Faderl, Stefan
    Bixby, Dale L.
    Chen, Janice
    Lindsay, Ross
    Shemesh, Shay
    Brooks, Christopher L.
    Stone, Richard M.
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    Konopleva, Marina
    BLOOD, 2016, 128 (22)
  • [29] Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)
    Popat, Rakesh
    De Tute, Ruth Mary
    Counsell, Nicholas
    De-Silva, Dunnya
    Phillips, Beth
    Cavenagh, James D.
    Adedayo, Toyin
    Braganza, Nivette
    Roddie, Claire
    Streetly, Mathew
    Schey, Stephen
    Koh, Mickey
    Crowe, Josephine
    Quinn, Michael F.
    D'Sa, Shirley
    Virchis, Andres E.
    Cook, Gordon
    Crawley, Charles R.
    Pratt, Guy
    Cook, Mark
    Smith, Paul
    Clifton-Hadley, Laura
    Rabin, Neil
    Owen, Roger G.
    Yong, Kwee
    BLOOD, 2017, 130
  • [30] Minimal residual disease (MRD) and risk of relapse in acute promyelocytic leukemia (APL): Insights from the north American intergroup phase III trial C9710.
    Stock, Wendy
    Harvey, Richard
    Moser, Barry
    Sher, Dorie
    Schachter-Tokarz, Esther
    Myers, Matthew
    Slack, James
    Powell, Bayard
    Bloomfield, Clara D.
    Larson, Richard A.
    Tallman, Martin S.
    Appelbaum, Frederick R.
    Feusner, James
    Willman, Cheryl
    Gallagher, Robert
    BLOOD, 2006, 108 (11) : 150A - 150A
12345